03rd week of 2015 patent applcation highlights part 42 |
Patent application number | Title | Published |
20150017141 | USE OF ICOS-BASED CARS TO ENHANCE ANTITUMOR ACTIVITY AND CAR PERSISTENCE - The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain. | 2015-01-15 |
20150017142 | COMPOSITION COMPRISING PROBIOTIC BACTERIA FOR USE IN THE TREATMENT OF IMMUNE DISORDERS - The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis. | 2015-01-15 |
20150017143 | COMPOSITION COMPRISING SPECIFIC LACTOBACILLUS HELVETICUS STRAINS AND REDUCING FOOD AND/OR RESPIRATORY ALLERGY SYMPTOMS - A composition comprising specific | 2015-01-15 |
20150017144 | COMPOSITIONS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE, METHODS OF THEIR USE AND METHODS OF MAKING THE SAME - Provided herein are compositions useful for the treatment or prevention of | 2015-01-15 |
20150017145 | Pharmaceutical Kits Comprising Mesenchymal Stem Cells - A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration of tendons in competitive mammals, such as the superficial digital flexor tendon of the horse. | 2015-01-15 |
20150017146 | METHOD OF ENHANCING EFFICACY OF BLOOD TRANSFUSIONS - A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion. | 2015-01-15 |
20150017147 | METHODS AND PRODUCTS TO PROVIDE ORAL NUTRITIONAL CARE TO SUBJECTS WITH DEMENTIA - The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm | 2015-01-15 |
20150017148 | NETRIN LOOP PEPTIDE MIMETICS AND USES THEREOF - In certain embodiments compositions are provided that comprise a pentapeptide comprising the formula: C | 2015-01-15 |
20150017149 | PHARMACEUTICAL OR NUTRITIONAL COMPOSITIONS CONTAINING GALACTOSIDASE, AND THEIR USE - The present disclosure relates to pharmaceutical or nutritional compositions containing α-galactosidase and β-galactosidase and their use in the prevention and/or treatment of gastroesophageal reflux disease; in particular the present disclosure related to pharmaceutical or nutritional compositions. | 2015-01-15 |
20150017150 | Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract - The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition. | 2015-01-15 |
20150017151 | PHARMACEUTICAL FORMULATIONS OF XANTHINE OR XANTHINE DERIVATIVES, AND THEIR USE - The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration. | 2015-01-15 |
20150017152 | COMPOSITION CONTAINING 4-OXOVALERIC ACID AND LEUCONOSTOC/RADISH ROOT FERMENT FILTRAT - A composition comprising 4-oxovaleric acid present in an amount of 0.05 to 1% by weight (as supplied) of the composition and leuconostoc/radish root ferment filtrate present at 0.2 to 2% by weight (as supplied) of the composition. | 2015-01-15 |
20150017153 | MONOCLONAL ANTIBODIES THAT NEUTRALIZE ANTHRAX TOXINS - The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 2015-01-15 |
20150017154 | ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME - A method of preparing an antibody suitable for use in a canine is provided. Also provided are caninised antibodies which specifically bind to canine neuronal growth factor (NGF) and neutralise the ability of canine NGF to bind to the p75 or TrkA canine NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in a canine using said antibodies and/or nucleic acids. | 2015-01-15 |
20150017155 | AGLYCOSYL ANTI-CD154 (CD40 LIGAND) ANTIBODIES AND USES THEREOF - The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the C | 2015-01-15 |
20150017156 | ESX-MEDIATED TRANSCRIPTION MODULATORS AND RELATED METHODS - The present invention relates to gene regulation. In particular, the present invention provides small compounds capable of modulating ESX-mediated transcription and related methods of therapeutic and research use. In addition, the present invention provides methods for treating conditions associated with aberrant EGFR expression with ESX-mediated transcription modulators (e.g., ESX-mediated transcription inhibitors). | 2015-01-15 |
20150017157 | METHODS FOR TREATING ACNE - The present disclosure relates to methods and materials for treating acne in a subject including, for example, moderate and/or severe acne, using anti-IL-1β binding molecules such as an anti-IL-1β antibody or binding fragment thereof. | 2015-01-15 |
20150017158 | TETRAHYDROFOLATES IN COMBINATION WITH EGFR-INHIBITORS - The present invention relates a pharmaceutical composition comprising an EGFR inhibitor and methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate, for use in the treatment of cancer. The methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate enhances the anticancer efficacy of the EGFR inhibitor. The cancers that may be treated include breast cancer, gastric cancer, gastrointestinal cancer, gall bladder cancer, bile duct cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck cancer, esophageal cancer, mesothelioma cancer, lung cancer including non-small-cell lung cancer, ovarian cancer, endometrial cancer, cervical cancer, peripheral T-cell lymphoma (PTCL), melanoma, brain tumors, adenocarcinoma, esophageal cancer, and osteosarcoma | 2015-01-15 |
20150017159 | MONOCYTE BIOMARKERS FOR CANCER DETECTION - The disclosure relates to the field of biomarkers to diagnose a disease, more particularly to the field of biomarkers to diagnose cancer, and most particularly to colorectal cancer. Specifically, these biomarkers are expressed in monocytes of a subject, particularly circulating monocytes, as can be isolated from peripheral blood. The markers are particularly useful for early detection of cancer. | 2015-01-15 |
20150017160 | COMBINATIONS AND USES THEREOF - The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib. | 2015-01-15 |
20150017161 | COMPOSITIONS AND METHODS FOR THE ALTERATION OF XLHED PHENOTYPES - The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED. | 2015-01-15 |
20150017162 | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same - In one aspect, the invention provides an isolated antibody, or antigen-binding fragment thereof, comprising a bioactive peptide amino acid sequence, wherein the bioactive peptide amino acid sequence is an inhibitor of the complement system and is fused to at least one of: (i) the amino terminal region of at least one of: a light chain variable region and/or a heavy chain variable region; or (ii) the carboxy terminal region of at least one of: a light chain constant region and/or a heavy chain constant region, wherein the antibody inhibits complement activation. | 2015-01-15 |
20150017163 | Methods for Treating or Preventing Ophthalmological Conditions - The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof. | 2015-01-15 |
20150017164 | COMBINATION OF BLyS AND/OR APRIL INHIBITION AND IMMUNOSUPPRESSANTS FOR TREATMENT OF AUTOIMMUNE DISEASE - The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases. | 2015-01-15 |
20150017165 | MONOCLONAL ANTIBODIES THAT INHIBIT THE Wnt SIGNALING PATHWAY AND METHODS OF PRODUCTION AND USE THEREOF - Monoclonal antibodies against LRP6 and that block the Wnt signaling pathway are disclosed. Methods of production and use thereof are also disclosed. | 2015-01-15 |
20150017166 | REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES - The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance. | 2015-01-15 |
20150017167 | ANTI-HUMAN CCR7 ANTIBODY, HYBRIDOMA, NUCLEIC ACID, VECTOR, CELL, PHARMACEUTICAL COMPOSITION, AND ANTIBODY-IMMOBILIZED CARRIER - An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer. | 2015-01-15 |
20150017168 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 2015-01-15 |
20150017169 | Sequence Asymmetric Modified IgG4 Bispecific Antibodies - The present disclosure provides an asymmetric mixed antibody comprising two heavy chains or heavy chain fragments each comprising at least a variable region, a hinge region and a CH1 domain, wherein a first heavy chain or fragment thereof is a class IgG4 and has: a the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, and wherein the second heavy chain or fragment thereof is characterised in that part or all of the chain has a different amino acid sequence to said first heavy chain in at least the region outside the variable region (for example the constant region), formulations comprising the same, therapeutic used of both of the above, and processes for preparing the antibodies and formulation. | 2015-01-15 |
20150017170 | BIOMARKER FOR SELECTING A SUBJECT FOR APPLICATION OF AN ANTI-C-MET ANTIBODY - A method of selecting a subject for administration of an anti-c-Met antibody, comprising (i) determining the presence or the amount of a ubiquitin peptidase, (ii) determining the presence or expression level of a ubiquitin peptidase coding gene, or (iii) measuring the activity of a ubiquitin peptidase, in a biological sample; as well as related methods. | 2015-01-15 |
20150017171 | Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcinoma - The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists. | 2015-01-15 |
20150017172 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER - This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or fragment thereof as an active ingredient. | 2015-01-15 |
20150017173 | ANTIBODIES TO HUMAN TRANSMEMBRANE PROTEINS - The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN. | 2015-01-15 |
20150017174 | Composition - The present invention relates to a composition for use in the treatment of an intestinal tract disorder caused by a gluten-associated protein, said composition comprising at least one agent which binds to the gluten-associated protein, characterized in that the composition is administered at the same time as or at most within 60 minutes after administration of at least one tannin to a patient. | 2015-01-15 |
20150017175 | METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 2015-01-15 |
20150017176 | METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R INHIBITOR - The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) inhibitor such as an anti-IL-4Rα antibody. | 2015-01-15 |
20150017177 | Injectable, Non-Aqueous Suspension with High Concentration of Therapeutic Agent - An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed. | 2015-01-15 |
20150017178 | Anti-CD26 Antibodies and Uses Thereof - The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts. | 2015-01-15 |
20150017179 | Method of Treatment and Bioassay Involving Macrophage Migration Inhibitory Factor (MIF) as Cardiac-Derived Myocardial Depressant Factor - One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody; a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor. | 2015-01-15 |
20150017180 | TREATMENT OF CHRONIC INFLAMMATORY CONDITIONS - A method for the treatment of a chronic inflammatory condition in a patient which comprises administration to the patient of an agent which blocks or inhibits IL-3 signalling events in the patient. | 2015-01-15 |
20150017181 | PREVENTION OF INFECTION - The invention relates to compositions and methods to prevent enteric infection in a subject at risk of such infection. In particular, the invention relates to the prevention of recurrence of infection by | 2015-01-15 |
20150017182 | METHODS FOR TREATING NASAL POLYPOSIS BY ADMINISTERING AN IL-4R ANTAGONIST - The present invention provides methods for treating nasal polyposis. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof. | 2015-01-15 |
20150017183 | SINGLE DOMAIN ANTIBODIES AS INHIBITORS OF PCSK9 - Antibodies (e.g., sdAbs) binding to PCSK9 are described. Nucleic acids encoding such Abs, host cells expressing such Abs and pharmaceutical composition comprising same are described. The use of these PCSK9-binding Abs for lowering low-density lipoprotein-cholesterol (LDL-C) levels and for the treatment of cardiovascular disorders, is also described. | 2015-01-15 |
20150017184 | IL-17 Receptor Antibody Formulation - The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease. | 2015-01-15 |
20150017185 | METHOD TO IMPROVE THE IMMUNE FUNCTION OF T CELLS - The present invention provides a method for enhancing the immune function of a memory T cell which comprises the step of coinhibting signalling via an inhibitory receptor which regulates T cell exhaustion and via the p38 MAP kinase signalling pathway in the T cell, and a method for treating and/or preventing an immune condition in a subject, which comprises the step of enhancing the immune function of a memory T cell in the subject by such a method. There is also provided a pharmaceutical composition or kit comprising an agent capable of inhibiting signalling via an inhibitory receptor which regulates T cell exhaustion, such as PD-1, and an agent capable of inhibiting the p38 MAP kinase signalling pathway. | 2015-01-15 |
20150017186 | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use - Provided are compositions and combinations containing an organophosphorus bioscavenger and a hyaluronan-degrading enzyme. The provided compositions and combinations can be used to treat or prevent organophosphorus poisoning, including nerve agent poisoning and pesticide poisoning. | 2015-01-15 |
20150017187 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE - Provided herein are antibodies comprising multiple non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis. | 2015-01-15 |
20150017188 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES - Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: | 2015-01-15 |
20150017189 | METHODS OF MAKING AND USING NANOSTRUCTURES - The invention provides methods for attaching drugs, dyes or radiolabels to bis-MTX. This method can be used to prepare bis-MTX analogs that can be used to deliver agents, such as nanoparticles, drugs, dyes or radiolabels, to cells. | 2015-01-15 |
20150017190 | USE OF EPITOPES INDUCING SPECIFIC TOLERANCE FOR THE PREVENTION OF TISSUE REJECTION - The present invention relates to a composition for use in the prevention of the rejection of skin tissue, comprising an effective amount of a peptide comprising an epitope of an antigen selected from the group of the polypeptides type XVII collagen, VII collagen, integrin alpha 6, integrin beta 4, chains of laminin, chains of laminin 322, type IV collagen, plectin, plakoglobin, bullous pemphigoid antigen 1, periplakin, envoplakin, desmoglein 1, desmoglein 3, a desmocollin and human bullous pemphigoid antigen 2 (hBPAG2) wherein said epitope induces immunological tolerance against its underlying polypeptide, and/or a nucleic acid for expressing a peptide comprising an epitope of said antigen as well as a gene therapy based on the composition, in the context of autoimmune blistering diseases, such as bullous pemphigoid or genetic skin diseases such as epidermolysisbullosa. | 2015-01-15 |
20150017191 | ADJUVANT FORMULATIONS COMPRISING TLR4 AGONISTS AND METHODS OF USING THE SAME - Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emulsion is greater than about 9. | 2015-01-15 |
20150017192 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS - The present invention relates to methods and reagents for use in site-selective modification of proteins having lysine residues with functionalized peptides using a chemoenzymatic microbial transglutaminase-mediated reaction. The functionalized proteins may be used for study or therapeutic uses. | 2015-01-15 |
20150017193 | RAB6KIFL/KIF20A EPITOPE PEPTIDE AND VACCINES CONTAINING THE SAME - The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents. | 2015-01-15 |
20150017194 | VIRUS LIKE PARTICLE COMPRISING PD-1 ANTIGEN OR PD-1 LIGAND ANTIGEN - The present invention provides a virus like particle comprising a virus structural protein and an antigen derived from PD-1 or a ligand of PD-1, and a composition or kit comprising thereof, its use in immune response etc. | 2015-01-15 |
20150017195 | PORCINE KNOB XENOTYPE CHIMERIC ADENOVIRAL VECTOR FOR DENDRITIC CELL INFECTION - Disclosed are methods of transforming dendritic cells with a chimeric adenovirus-5 (Ad5). A chimeric adenovirus includes a fiber comprising a tail, a shaft and a knob, wherein the knob is a porcine knob, and a nucleic acid comprising a promoter operably linked to a heterologous sequence encoding an antigen peptide. | 2015-01-15 |
20150017196 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H5N1 AND H1N1 INFLUENZA VIRUSES - Described herein is the generation of optimized H5N1 and H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on H5N1 and H1N1 influenza isolates. Provided herein are optimized H5N1 and H1N1 influenza HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure. | 2015-01-15 |
20150017197 | HCV VACCINES AND METHODS FOR USING THE SAME - Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a/1b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed. | 2015-01-15 |
20150017198 | MUTATED AND BACTERIOPHAGE T4 NANOPARTICLE ARRAYED F1-V IMMUNOGENS FROM YERSINIA PESTIS AS NEXT GENERATION PLAGUE VACCINES - Techniques from two basic approaches, structure-based immunogen design and phage T4 nanoparticle delivery, are developed to construct new plague vaccines. The NH | 2015-01-15 |
20150017199 | CHOLERA TOXIN CHIMERA AND ITS USE AS A STAPH VACCINE - The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of | 2015-01-15 |
20150017200 | FUSION PROTEINS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF LEISHMANIASIS - The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the | 2015-01-15 |
20150017201 | NOVEL NICOTINE DNA VACCINES - The present invention provides DNA-nanostructures comprising and at least one targeting moiety, wherein the at least one targeting moiety is linked to the DNA-nanostructure; and wherein the at least one targeting moiety is nicotine or a nicotine analogue. These compounds elicit an immunogenic response in individuals and are useful as vaccines for ameliorating nicotine dependence. | 2015-01-15 |
20150017202 | SYNTHETIC TOLL-LIKE RECEPTOR-4 (TLR-4) AGONIST PEPTIDES - The invention provides novel immunological adjuvants and methods for identification of such adjuvants. The invention further provides methods and compositions for eliciting an immune response to an immunogen using the novel adjuvants. The adjuvants can be employed with any suitable immunogen, including proteins, peptides, lipids, and carbohydrates. The immunogen can be derived from a virus, a cancer, or a diseased cell. The elicited immune response can be cellular, humoral, or both. | 2015-01-15 |
20150017203 | COMBINATION PRODUCT FOR TREATING EXCESS WEIGHT AND/OR FOR IMPROVING THE FIGURE - A combination product includes as active substances, at least an inhibitor of the HMG-CoA-reductase enzyme and citrulline, or a bioequivalent compound thereof, for treating excess weight or obesity and/or the accumulation of body fat. A cosmetic treatment method for improving or slimming the figure and/or for stimulating the loss of excess weight and/or of cellulite and/or for limiting the accumulation thereof, includes the administration of a combination product including as active substances, at least an inhibitor of the HMG-CoA-reductase enzyme or a physiologically acceptable salt thereof, and citrulline, or a bioequivalent compound thereof, or one of theirs analogues, and the renewal of the administration until the expected cosmetic effect is obtained. The combination product such as previously defined for improving or slimming the figure and/or for stimulating the loss of excess weight and/or of cellulite and/or for limiting the accumulation thereof is also described. | 2015-01-15 |
20150017204 | LIVE BACTERIAL VACCINES RESISTANT TO CARBON DIOXIDE (CO2), ACIDIC PH AND/OR OSMOLARITY FOR VIRAL INFECTION PROPHYLAXIS OR TREATMENT - The present invention relates to gram-negative bacterial mutants resistant to one or more stress conditions, including, but not limited to, CO | 2015-01-15 |
20150017205 | HIGH TITER RECOMBINANT INFLUENZA VIRUSES WITH ENHANCED REPLICATION IN MDCK OR VERO CELLS OR EGGS - The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer enhanced growth in cells in culture, such as MDCK cells, or in eggs. | 2015-01-15 |
20150017206 | ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION - An improved method for the manufacture of an oil-in-water emulsion comprises using a microfluidisation device whose interaction chamber comprises a plurality of Z-type channels upstream of a back pressure chamber. | 2015-01-15 |
20150017207 | Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling - Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome. | 2015-01-15 |
20150017208 | LACTIC ACID BACTERIUM HAVING IMMUNOMODULATORY AND ANTI-ALLERGIC EFFECTS - A novel lactic acid bacterium strain having immunomodulatory and anti-allergic effects in a subject is disclosed. | 2015-01-15 |
20150017209 | Composition for Immunization Against Streptococcus Pneumoniae - This disclosure relates to a method of preventing or treating a recurrence of acute otitis media in a subject at risk comprising administering a therapeutically effective amount of a composition, at least once to the subject. The composition administered comprises at least one immunogenic polypeptide selected from the group consisting of | 2015-01-15 |
20150017210 | Gene Signature Predicts Adenocarcinoma Prognosis and Therapeutic Response - The present invention is drawn to methods of predicting prognosis of, and therapeutic response in, carcinoma of the lung. | 2015-01-15 |
20150017211 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS - Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins. | 2015-01-15 |
20150017212 | Preparation for Transnasal Application - Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties, and physiologically active substance. | 2015-01-15 |
20150017213 | Ocular Composition and Kits Thereof - An ocular composition consisting essentially of purified water, PEG-80 sorbitan laurate, sodium trideceth sulfate, PEG-150 distearate, sodium lauroamphoacetate, cocamidopropyl hydroxysultaine, sodium laureth-13 carboxylate, sodium chloride, PEG-15 cocopolyamine, polyhexamethylene biguanide, potassium sorbate, 1,2 hexanediol, and caprylyl glycol. The composition can be applied to a fabric pad for use as an eyelid cleanser, where the fabric pad is pre-moistened with the composition and packaged for use. The composition may also be used in an eyelid treatment kit for convenient combination treatments to improve overall eyelid hygiene and adjunctive eyelid therapy. | 2015-01-15 |
20150017214 | MICROCAPSULES - A microcapsule having an average particle size of from 7.5 to 50 microns. The microcapsule contains a core and a polymeric shell enclosing the core. The core contains a core material containing an emulsifiable fragrance. The polymeric shell contains, in polymerized form, a monomer blend containing: the specific monomer (i) in an amount of from 30% to 80% by weight over the combined weight of monomers (i) and (ii); and the specific monomer (ii) in an amount of 20% to 70% by weight over the combined weight of monomers (i) and (ii). | 2015-01-15 |
20150017215 | CLEANING WIPE FOR USE WITH DISINFECTANTS, METHOD OF MANUFACTURE THEREOF, AND SYSTEM - A cleaning wipe includes a dry substrate comprising nonwoven synthetic fibers, wherein the fibers have a fineness of about 2.3 denier to about 3.3 denier; and a nonionic surfactant disposed on the dry substrate, wherein the surfactant is present on the dry substrate at an add-on level of about 0.1 weight percent to about 1.5 weight percent, based on the weight of the dry substrate, and wherein the cleaning wipe is active disinfectant stable. | 2015-01-15 |
20150017216 | COMPOSITIONS AND METHODS FOR TARGET DELIVERING A BIOACTIVE AGENT TO AQUATIC ORGANISMS - Biodegradable and nutritionally attractive composition comprising biocidal or antibiotic compounds and/or microbes having bio-adhesion and controlled buoyancy properties are selectively fed to an aquatic organism in open or closed water-bodies, and bioactive components are released upon contact with mucosal tissues such as gill, skin or along the digestive tract of the selected aquatic organism. | 2015-01-15 |
20150017217 | PESTICIDAL COMPOSITIONS FOR INSECTS AND ARTHROPODS - The present invention provides an insect or arthropod pesticidal composition. The composition includes active ingredients having a mixture of fatty acids, each of the fatty acids having a straight carbon chain from 6 to 12 carbon atoms long. The fatty acid mixture includes a first fatty acid molecule having a straight carbon chain from 6 to 8 carbon atoms long, and a carboxylic acid group. The fatty acid mixture also includes a second fatty acid molecule having a straight carbon chain from 8 to 12 carbon atoms long, and a carboxylic acid group. The composition also includes a carrier that promotes adherence or absorption or transport across the surface of insects or arthropods to effect their incapacitation or death. | 2015-01-15 |
20150017218 | CLEANSING COMPOSITION HAVING A PRESERVATIVE SYSTEM AND A WET WIPE COMPRISING THE CLEANSING COMPOSITION - A wet wipe includes a cleansing composition and a substrate. The cleansing composition includes a preservative enhancing agent selected from the group consisting of caprylyl glycol; caprylyl glyceryl ether; glyceryl caprylate; sorbitan caprylate; ethylhyexyl glycerin, and combinations thereof. The cleansing composition includes a preservative selected from the group consisting of benzoic acid; lactic acid; sorbic acid; malic acid; maleic acid, and combinations thereof. The cleansing composition has a pH less than about 4. A method of making the cleansing composition may include dissolving one or more preservatives with water to form a solution; adding a rheology modifier to the solution; adding an emulsifier to the solution; adding a preservative enhancing agent to the solution; and adding citric acid to the solution. | 2015-01-15 |
20150017219 | SOLVENT METHODS FOR PREPARING CRYSTALLINE MACROLIDE PARTICULATES, COMPOSITIONS, AND ARTICLES CONTAINING PARTICULATES - The invention provides therapeutic particulates including a macrolide, such as rapamycin, in solid state crystalline form, having a size of 20 μm or less, or 10 μm or less. The particulates are formed in one method by preparing a composition with a macrolide and first (e.g., xylene) and second (e.g., an alcohol, acetone, or acetonitrile) solvents. In the composition a maximum solubility for the macrolide that is greater than a maximum solubility of the macrolide dissolved in either the first or second solvent individually. The first and second solvents are then evaporated from the composition to provide the macrolide particulates. In another method, the particulates can be formed by a method including sonication and stirring/evaporation steps, and the particulates can be obtained from a supersaturated solution, formed during the process. Particulates display desirable low polydispersity, and can be used in therapeutic compositions, or can be associated with an implantable or insertable medical device for the treatment of a subject. | 2015-01-15 |
20150017220 | Rapid Preparation of Stem Cell Matrices for Use in Tissue and Organ Treatment and Repair - A rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair is described. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo applications. The stem cells can be from numerous sources and may be homogeneous, heterogeneous, autologous, and/or allogeneic in the matrix material. The stem cell-matrix compositions provide point of service utility for the practitioner, wherein the stem cells and matrix can be combined not long before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural properties to the matrix composition which improves outcome and healing after use. Use of stem cells obtained from muscle affords contractility to the matrix composition. | 2015-01-15 |
20150017221 | CELL ADHESION INHIBITOR - Provided is a cell adhesion inhibitor which exhibits low cytotoxicity and an excellent cell adhesion prevention effect; a tool and an apparatus each having a surface modified through application of the cell adhesion inhibitor thereto; a method for producing each of the surface-modified tool and apparatus; a biomedical structure and a production method therefor; and a microchannel device and a production method therefor. | 2015-01-15 |
20150017222 | Disrupted Cartilage Products - This invention provides disrupted cartilage products, methods of manufacturing disrupted cartilage products, and methods of treating a subject comprising administering a cartilage product. The cartilage products are manufactured by a method comprising disrupting a collagen matrix, e.g. to produce a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic. | 2015-01-15 |
20150017223 | EDIBLE COATING COMPOSITION AND USES THEREOF - Described herein is an edible coating for food products in which the coatings comprises a polysaccharide cross-linked with a cross-linking agent solution. Also described herein are methods for coating food products and forming clusters of food products. The use of the edible coating for extending the shelf-life of food products is also described. | 2015-01-15 |
20150017224 | METHOD FOR PRODUCING A TISSUE PAPER SHEET MATERIAL CONTAINING AN ADJUVANT SUBSTANCE FOR THE TREATMENT OF ALLERGIC RHINITIS, AND THE PRODUCT OBTAINED - The following steps are provided for producing a sheet cellulose material, for instance a handkerchief, comprising at least one adjuvant substance for the treatment of allergic rhinitis:
| 2015-01-15 |
20150017225 | Hemostatic Pad Assembly Kit and Method - The present invention relates generally to agents and devices for promoting hemostasis and tissue sealing and, more particularly, to hemostatic pads comprising bioabsorbable scaffolds that can deliver lyophilized hemostasis promoting proteins, such as fibrinogen and thrombin, to a wound site or injured organ or tissue. | 2015-01-15 |
20150017226 | TOLTERODINE-CONTAINING ADHESIVE PATCH - The present invention provides a tolterodine-containing patch in which an adhesive layer is laminated on a backing, characterized in that the adhesive layer is obtainable by adding tolterodine to an adhesive base comprising a rubber adhesive, a tackifier resin, and a softener, wherein the tolterodine is present in the form of a free base in the adhesive base. | 2015-01-15 |
20150017227 | Methods and Compositions for Treating Skin Diseases and Conditions - Disclosed are methods and compositions for treating skin diseases or conditions with a composition containing a lipid component as an active ingredient. | 2015-01-15 |
20150017228 | METHOD AND SYSTEM FOR SYNTHESIZING NANOCARRIER BASED LONG ACTING DRUG DELIVERY SYSTEM FOR MORPHINE - The embodiments herein provide a nano-carrier system for delivering a long-acting injectable drug of morphine and a method of synthesising the same. The morphine entrapped nanoparticles are prepared using a lipid/phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is transferred into an aqueous phase consisting of distilled water or a buffer. A solution of polymer is added drop wise. The drug entrapped nanoparticle formation is achieved by diffusion of the organic solvent within the aqueous solvent to obtain the nanoparticles. The drug gets entrapped within the nanoparticles via the anti-solvency effect of the aqueous matrix. The resulting drug nanocarriers are capable of releasing the drug in a slow rate upon injection. The synthesized drug carrying nanoparticles are cryopreserved stored for future administration. For better storage, the nanodispersion is dried to form a powder. | 2015-01-15 |
20150017229 | METHOD AND SYSTEM FOR SYNTHESIZING NANOCARRIER BASED LONG ACTING DRUG DELIVERY SYSTEM FOR INSULIN - The embodiments herein provide a long-acting injectable drug (insulin) delivery nano-carrier system and a method of synthesising the same. The insulin entrapped nanoparticles are prepared using a lipid/phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is transferred into an aqueous phase consisting of distilled water or a buffer and dissolved insulin. A solution of polymer is added drop wise. The drug entrapped nanoparticle formation is achieved by diffusion of the organic solvent within the aqueous solvent to obtain the nanoparticles. The drug gets entrapped within the formed nanoparticles via the anti-solvency effect of the aqueous matrix. The resulting drug nanocarriers are capable of releasing the drug in a slow rate upon injection. The synthesized drug carrying nanoparticles are cryopreserved stored for future administration. For better storage the nanodispersion is dried to form a powder. | 2015-01-15 |
20150017230 | ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF - An isolated monoclonal antibody or an antigen-binding fragment thereof is disclosed. The antibody or the antigen-binding fragment is characterized by: (a) having a specific binding affinity to epithelial cell adhesion molecule (EpCAM) comprising the amino acid sequence of SEQ ID NO: 1; (b) having a specific binding affinity to cancer cells expressing EpCAM said cancer cells being selected from the group consisting of oral cancer cells, nasopharyngeal cancer cells (NPC), colorectal cancer cells, and ovarian cancer cells; and (c) having no binding affinity to human umbilical vein endothelial cell (HUVEC) and normal nasal mucosal epithelia (NNM). Also disclosed is an isolated monoclonal antibody or an antigen-binding fragment thereof that has a specific binding affinity to an epitope within the sequence of KPEGALQNNDGLYDPDCDE (SEQ ID NO: 63) located within the EGF-like domain II of epithelial cell adhesion molecule (EpCAM). Methods of using the same are also disclosed. | 2015-01-15 |
20150017231 | POLYAMINE TRANSPORT SELECTIVE THERAPEUTIC AGENTS WITH ENHANCED STABILITY - Disclosed herein are di-substituted aryl polyamine compounds and methods of making and using the same. The di-substituted polyamine compounds act as PTS targeting agents, which selectively target the polyamine transport system (PTS) with high efficacy and have improved stability in the presence of amine oxidases. | 2015-01-15 |
20150017232 | OLIGOPEPTIDIC COMPOUNDS AND USES THEREOF - Disclosed is an oligopeptidic compound capable of interacting with proliferating cell nuclear antigen (PCNA), wherein the compound comprises a PCNA interacting motif which is: | 2015-01-15 |
20150017233 | ARGININE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS - This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects. | 2015-01-15 |
20150017234 | INCREASED EFFECTIVENESS OF ALLYLAMINE DRUG COMPOUNDS FOR TOPICAL TREATMENT OF FUNGAL INFECTIONS OF THE SKIN AND SKIN APPENDAGES - The invention is an increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of skin and skin appendages. The allylamine active ingredient is prepared in an acidic environment; the acidic environment altering the physiochemical properties of the active ingredient resulting in the active ingredient having a positive charge. The positive charge and enhancers used in the formula allow for increased penetration of the active ingredient through skin and skin appendages. The positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle. The bead structure minimizes the molecular diffusion of the positively charged active ingredient and a catalytic species through the bead structure, thus stabilizes the positively charged active ingredient inside the bead by impeding the interaction of the positively charged active ingredient and the catalytic species, and thereby extending the shelf life of the positively charged active ingredient. | 2015-01-15 |
20150017235 | LIPOSOMES ACTIVE IN-VIVO ON NEURODEGENERATIVE DISEASES - New liposomes are described, comprising: (i) phosphatidic acid and/or cardiolipin; (ii) apolipoprotein E (ApoE) or derivatives thereof. The so modified liposomes, administered systemically, obtain a dramatic in-vivo reduction of the amyloid plaque in the central nervous system, allowing an effective treatment of neurodegenerative diseases, in particular Alzheimer's disease. | 2015-01-15 |
20150017236 | PHARMACEUTICAL COMPOSITIONS OF THYROID HORMONE - Provided herein are methods of stabilizing thyroid hormone, preventing a thyroid hormone from being oxidized, producing a formulation of thyroid hormone having a uniform potency, and reducing the exposure of a thyroid hormone to oxygen, light, moisture, or high temperature. Such methods comprise coating said thyroid hormone to provide a solid form comprising thyroid hormone coated with a coating material. Also provided are pharmaceutical compositions comprising a solid form of a thyroid hormone, wherein said solid form comprises thyroid hormone coated with a coating material. The invention also provides pharmaceutical compositions produced by the methods. Unit dosage forms and batches comprising such pharmaceutical compositions are also provided. | 2015-01-15 |
20150017237 | DOSAGE FORM COMPRISING LOPINAVIR AND RITONAVIR - The present invention relates to an oral dosage form comprising crystalline lopinavir and crystalline ritonavir. The invention further relates to methods of preparing said oral dosage forms containing the above pharmaceutical active agents. | 2015-01-15 |
20150017238 | METHODS AND COMPOSITIONS FOR TREATING DIABETES - Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue. | 2015-01-15 |
20150017239 | METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENT - The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions. | 2015-01-15 |
20150017240 | PHARMACEUTICAL COMPOSITIONS COMPRISING A PH-DEPENDENT COMPONENT AND PH-RAISING AGENT - An oral pharmaceutical composition in unit dosage form comprising: (1) a first portion comprising: an active ingredient and a pH-dependent component, and (2) a second portion comprising a pH-raising agent is provided. Methods of administering the composition are also provided. | 2015-01-15 |